Sorafenib resulted in significantly improved progression-free survival (PFS) compared with placebo in patients with desmoid tumors (DTs) or aggressive fibromatosis, according to results of a randomized phase III trial presented on June 4 (Abstract 11500).
In contrast to more common cancers, some sarcoma subsets are fairly rare and standard treatments have not been established. However, for each sarcoma type discussed, strategies are being developed with the aim of improving outcomes for patients with sarcoma.
High-dose busulfan-melphalan followed by autologous stem cell rescue may be an effective treatment for highly selected patients with localized high-risk Ewing sarcoma but does not provide a significant efficacy benefit in patients with lung metastases, suggest results from two randomized trials.
The Center for Cancer and Blood Disorders is participating in the COME HOME project, an innovative medical home model with the goal of improving health outcomes, enhancing patient care experiences, and significantly reduce costs of care.
In his overview of GeDDiS, discussant Dr. Laurence H. Baker called upon the sarcoma research community to agree on standard criteria for trials of this nature to accelerate the delivery of better therapies for patients with STS.
In a randomized, open-label phase III trial, trabectedin failed to show OS improvement over dacarbazine in patients with advanced liposarcoma or leiomyosarcoma but it did show a significant improvement in progression-free survival.
The PET-NECK trial was conducted to evaluate the efficacy and cost-effectiveness of PET-CT guided surveillance compared with planned neck dissection in patients with head and neck squamous cell carcinoma.